Adverse effects of intraportal chemotherapy on natural killer cell activity in colorectal cancer patients

Journal of Surgical Oncology

Volumn 64, Issue 4, 1997, Pages 324-330

  Rafique, Mohammad ^a   Adachi, Wataru ^a   Koike, Shoichiro ^a   Kajikawa, Shoji ^a   Yazawa, Kazuyuki ^a   Sugenoya, Akira ^a   Amano, Jun ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 fluorouracil; hepatic metastases; immunosuppressive acidic protein (IAP); mitomycin C; natural killer cell activity; T cell subpopulations

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; FLUOROURACIL; MITOMYCIN C;

ADULT; AGED; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS; LYMPHOCYTE SUBPOPULATION; MALE; NATURAL KILLER CELL; PORTAL VEIN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 0030888398     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199704)64:4<324::AID-JSO14>3.0.CO;2-2     Document Type: Article

References (29)

1. Taylor I, Brooman P, Rowling JT: Adjuvant liver perfusion in colorectal cancer: Initial results of a clinical trial. Br Med J 1977; 2:1320-1322.
2. Morales F, Bell M, McDonald GO, Cole WH: The prophylactic treatment of cancer at the time of operation. Ann Surg 1957; 146:588-593.
3. Fisher ER, Turnbull RB Jr: The cytologic demonstration and significance of tumor cells in the mesenteric venous blood in patients with colorectal carcinoma. Surg Gynecol Obstet 1955;100:102-108.
4. Cruz EP, McDonald GO, Cole WH: Prophylactic treatment of cancer: The use of chemotherapeutic agents to prevent tumor metastasis. Surgery 1956;40:291-296.
5. Taylor I, Machin D, Mullee M, et al.: A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br J Surg 1985;72:359-363.
6. Fielding LP, Hittinger R, Grace RH, Fry JS: Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma. Lancet 1992;340:502-506.
7. Wolmark N, Rockette H, Wickerham DL, et al.: Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: Preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. J Clin Oncol 1990;8:1466-1475.
8. Wereldsma JCJ, Bruggink EDM, Meijer WS, et al.: Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control: Results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I). Cancer 1990;65:425-432.
9. Ryan J, Weiden P, Crowley J, Bloch K: Adjuvant portal vein infusion for colorectal cancer: A 3-arm randomized trial [abstract]. Proc Am Soc Clin Oncol 1988;7:95A.
10. Swiss Group for Clinical Cancer Research (SAKK): Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Lancet 1995;345:349-353.
11. Rafique M, Adachi W: Effects of intraportal administration of chemoimmunotherapeutic agents on natural killer cell activity in the rat liver. J Surg Oncol 1995;60:154-159.
12. Ichino Y, Ishikawa T: Cytolysis of autologous fresh osteosarcoma cells by human cytotoxic T lymphocytes propagated with T cell growth factor. Gann 1983;74:584-594.
13. Balch CM, Tilden AB, Dougherty PA, et al.: Depressed levels of granular lymphocytes with natural killer (NK) cell function in 247 cancer patients. Ann Surg 1983;198:192-199.
14. Tartter PI, Martinelli G, Steinberg B, Barron D: Changes in peripheral T-cell subsets and natural-killer cytotoxicity in relation to colorectal cancer surgery. Cancer Detect Prev 1986;9:359-364.
15. Tartter PI, Steinberg B, Barron DM, Martinelli G: The prognostic significance of natural killer cytotoxicity in patients with colorectal cancer. Arch Surg 1987;122:1264-1268.
16. Pross HF, Lotzová E: Role of natural killer cells in cancer. Nat Immun 1993;12:279-292.
17. Tønnesen E, Hüttel MS, Christensen NJ, Schmitz O: Natural killer cell activity in patients undergoing upper abdominal surgery: Relationship to the endocrine stress response. Acta Anaesthesiol Scand 1984;28:654-660.
18. Tønnesen E, Wahlgreen C: Influence of extradural and general anaesthesia on natural killer cell activity and lymphocyte subpopulations in patients undergoing hysterectomy. Br J Anaesth 1988;60:500-507.
19. Samuelson J, von Lichtenberg F: Diseases of immunity. In Cotran RS, Kumar V, Robbins SL (eds): "Robbins Pathologic Basis of Disease," 5th ed. Philadelphia: W.B. Saunders, 1994,171-240.
20. Tomkinson BE, Wagner DK, Nelson DL, Sullivan JL: Activated lymphocytes during acute Epstein-Barr virus infection. J Immunol 1987;139:3802-3807.
21. Tamura K, Shibata Y, Matsuda Y, Ishida N: Isolation and characterization of an immunosuppressive acidic protein from ascitic fluids of cancer patients. Cancer Res 1981;41:3244-3252.
22. Shimizu N, Yamane T, Karino T, et al.: Immunosuppressive acidic protein (IAP) in gastric cancer patients. Jpn J Surg 1983; 13:312-316.
23. Oka M, Mitsunaga H, Hazama S, et al.: Natural killer activity and serum immunosuppressive acidic protein levels in esophageal and gastric cancers. Surg Today 1993;23:669-674.
24. 1-acid glycoprotein, in connection with its high level in tumor-bearing mice. Cancer Res 1983;43:2889-2896.
25. Sawada M, Okudaira Y, Matsui Y, Shimizu Y: Immunosuppressive acidic protein in patients with ovarian cancer. Cancer 1983; 52:2081-2085.
26. Fujimoto S, Minami T, Ishigami H, et al.: Further studies on immunosuppressive acidic protein (IAP) in gastrointestinal cancer patients - with particular emphasis on relation to immunologic parameters. Jpn J Cancer Clin 1981;27:222-226 (Jpn).
27. Saijo N, Ozaki A, Beppu Y, et al.: Analysis of metastatic spread and growth of tumor cells in mice with depressed natural killer activity by Anti-asialo GM1 antibody or anticancer agents. Cancer Res Clin Oncol 1984;107:157-163.
28. Wiltrout RH, Herberman RB, Zhang S, et al.: Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver. J Immunol 1985;134:4267-4275.
29. Ishida H, Iwama T, Ide A, et al.: An experimental study on portal infusion of 5-fluorouracil. Jpn J Cancer Chemother 1992; 19:1532-1535 (Jpn).